BioStock: All patients have completed treatment in Follicum’s phase IIa trial

For Follicum, one of this year’s main events will be the topline result from the ongoing phase IIa study with the company’s candidate FOL-005 for treatment of hair loss. The company announced on Thursday that all patients in the study have undergone treatment and that results are expected in the spring. BioStock talked to Follicum’s CEO Jan Alenfall to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/all-patients-have-completed-treatment-in-follicums-phase-iia-trial/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se